Georges Gebrael @ggebraelmd Twitter profile

Pinned Tweet

Georges Gebrael

5 months

Very honored to receive the @ConquerCancerFd merit award #ASCO24 ! Despite challenges, it’s been a rewarding year. Grateful for my amazing support system, incredible team at @Huntsman_GU @huntsmancancer , and great mentorship of @neerajaiims ! See you all at #ASCO24 !

Georges Gebrael

@ggebraelmd

1 year

I am incredibly honored to have received the @ConquerCancerFd Merit Award #ASCO2023 !! Thanks to the unwavering support of my mentors, colleagues and friends. Thank you @neerajaiims , @ASCO and @huntsmancancer

24

10

139

20

11

100

Last Seen Profiles

@aBookPublicist

@ChardCricket

@4estRangers

@emanraka0

@ebukssssss

@kumachan9810

@iambeckyg

@mangapark_PR3

@Archaeometry

@tatrtotfreak420

@41lolo1

@PWLadyClassic

@Asim_525

@voicethread

@Blissfull_y

@OutburstArts

@SubmissionSFL

@Aerahana_

@d_sh_cooper

@kuuuunq

@IRDeptNDU

@nongcream_x

@FE1974_2022

@inheritanceplay

@bokeplokalmalam

@sofiyjulian2

@westernuLaw

@stw_pdg

@Pnar56924623

@Su1996_520

@thedanielblanco

@ahmedmona111111

@EastHbch

@AsianTVAwards

@CristianH99X

@eelsuurdeet

Georges Gebrael

@ggebraelmd

6 months

Unreal feeling! I am honored to match @UofUInternalMed Wouldn't be possible without the tremendous support from my family, friends, colleagues & specially my mentors and team who believed in me @neerajaiims @umangtalking @maughanonc @montypal Excited for what's ahead #Match2024

62

12

238

Georges Gebrael

@ggebraelmd

1 year

Hello #MedTwitter ! I am Georges Gebrael, IMG from Lebanon 🇱🇧, currently doing research at @huntsmancancer @UUtah . I'm extremely happy to be applying to #InternalMedicine for #Match2024 . Looking forward to connect with programs and applicants! #InsidetheMatch

42

29

209

Georges Gebrael

@ggebraelmd

1 year

I am incredibly honored to have received the @ConquerCancerFd Merit Award #ASCO2023 !! Thanks to the unwavering support of my mentors, colleagues and friends. Thank you @neerajaiims , @ASCO and @huntsmancancer

24

10

139

Georges Gebrael

@ggebraelmd

2 years

I am very excited to join the @huntsmancancer as a post doctoral research fellow at the GU #oncology department. Looking forward to this exceptional opportunity.

16

3

98

Georges Gebrael

@ggebraelmd

5 months

Just in @JournalCancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results @urotoday @OncoAlert @huntsmangu @umangtalking @neerajaiims 👇

8

36

96

Georges Gebrael

@ggebraelmd

2 years

👉Just in Biomedicines: high concordance between tissue and blood for BRCA mutations. Testing cfDNA➡️reliable information on BRCA mutational status➕viable alternative to solid tissue sequencing when unavailable #ProstateCancer Free access link @OncoAlert

8

36

90

Georges Gebrael

@ggebraelmd

8 months

Just in #GU24 👉Thrilled to be highlighted in #ASCODailyNews @ASCO to discuss pt-level analysis of Phase 3 SWOG1216 @SWOG in mHSPC #prostatecancer 👉Baseline bone pain correlated w/ poor PFS & OS 👇 @neerajaiims @NeliMUlrich @umangtalking @Huntsman_GU

10

24

78

Georges Gebrael

@ggebraelmd

1 year

Just in 👉Our latest paper discusses @PBarataMD et al. crucial work assessing treatment intensification in Europe & the US, as well as treatment decisions in 1L mCRPC during the era of ADT intensification @neerajaiims @umangtalking @vinay_onc ➡️

7

23

66

Georges Gebrael

@ggebraelmd

2 years

A great start for #GU23 @ASCO @DanaFarber_GU @Huntsman_GU @DrChoueiri @neerajaiims

4

6

61

Georges Gebrael

@ggebraelmd

1 year

👇Trial of ADT + ARPI vs. ADT + ARPI + docetaxel is needed; meanwhile ➡️disease & pt characteristics, Rx toxicities may guide #mHSPC #prostatecancer treatment selection @urotoday @PCFnews

ASCO

@ASCO

1 year

. @ggebraelmd , @nsayeghmd & @umangtalking of @huntsmancancer unpack recent #ClinicalTrial data & answer the question: When would you use doublet therapy & not triplet therapy for a patient w/ newly diagnosed #mHSPC ? #ASCODailyNews #GUCSM

0

7

16

2

31

57

Georges Gebrael

@ggebraelmd

1 year

Happy to share our latest review on IO-based combinations in first-line Rx in mRCC @tandfonline @maughanonc @neerajaiims @sahuonc Consistent ⬆️ outcomes with IO-based Rx with promising combinations underway 👉 biomarkers needed to optimize Rx selection

6

15

51

Georges Gebrael

@ggebraelmd

1 year

The #ASCOdailynews highlights SPOP mutation as a first biomarker for better response to ARPIs vs. docetaxel in de novo mCSPC. Further investigation of biomarkers is necessary to enhance the personalization of mCSPC treatment @umangtalking @nsayeghmd @Huntsman_GU

ASCO

@ASCO

1 year

SPOP mutations are the first predictive biomarker for treatment selection in de novo mHSPC; @ggebraelmd , @nsayeghmd & @umangtalking discuss the implications: #pcsm #ASCODailyNews

0

4

17

4

16

51

Georges Gebrael

@ggebraelmd

1 year

Just in @OncJournal 👉Molecular targets and racial disparities in translocation RCC, and directions for future drug development #kidneycancer @neerajaiims #patrickcampbell @OncoAlert @urotoday @huntsman_GU ➡️

3

17

46

Georges Gebrael

@ggebraelmd

2 years

Beautiful sunset-run with @PTarantinoMD @nsayeghmd at #SaltLakeCity after the very enriching #precisionmedicine summit organized by the @btfoundation

1

41

Georges Gebrael

@ggebraelmd

3 months

En route to #ASCO24 @ASCO 👉 For all interested in GU cancers, here’s a compiled list of GU sessions & a map of the McCormick @OncoAlert @urotoday

0

17

38

Georges Gebrael

@ggebraelmd

6 months

Now @EUplatinum : Exploratory analysis of TITAN by @SouMyajiT_RO @DrSpratticus 👉 Prior Local Rx 👉 no compromise of ADT + Apa efficacy & ⬆️ OS (even after adj for mets stage at PCa Dx) in pts w/ mHSPC #prostatecancer treated w/ ADT + Apa @urotoday 👉

3

17

37

Georges Gebrael

@ggebraelmd

7 months

Congrats @rebeccahassoun for this very important study @ASCO #GU24 👉 detection of ctDNA was associated w/significantly shorter EFS in pts w/ NSGCT #testicularcancer @nabiladra @OncoAlert

3

11

36

Georges Gebrael

@ggebraelmd

10 months

Just in @JCOPO_ASCO 👉 SPOP mutations drive opposing molecular and immune landscapes in #prostatecancer & #endometrialcancer by @EAntonarakis et al 👉 Check out our editorial 👉 @umangtalking @ZeynepZengin @Huntsman_GU @YaleIMed

1

13

34

Georges Gebrael

@ggebraelmd

1 year

#KCRS23 @eddy_saad elegantly presenting data on host immune signatures and clinical outcomes in patients with mRCC #kidneycancer @kidneycan

1

5

33

Georges Gebrael

@ggebraelmd

8 months

Happening now @ASCO #GU24 👇 As usual @montypal delivering a wonderful talk on lessons learned from other disease sites and its implications in urothelial cancer #bladdercancer @CityofHope_GU

1

5

31

Georges Gebrael

@ggebraelmd

1 year

Ab #4555 #ASCO23 @ASCO : In this @IMDConline study➡️no association between smoking status at diagnosis (never vs former vs current) & OS or TTF in pts with mRCC receiving 1st line Rx with ICI based combinations @neerajaiims @DrChoueiri @DrDanielHeng ➡️

1

12

31

Georges Gebrael

@ggebraelmd

8 months

CONTACT02 trial @ASCO #GU24 by @neerajaiims 👉Cabo + atezo vs. 2nd NHT in pts w/ mCRPC 👉 primary endpoint met with rPFS benefit (HR 0.65); benefit more pronounced in pts with liver mets @huntsmancancer @Huntsman_GU

0

12

29

Georges Gebrael

@ggebraelmd

8 months

Thank you @DrChoueiri , faculty, and @OncLive for this wonderful meeting #GU24 !

Toni Choueiri, MD

@DrChoueiri

8 months

Superb presentation by rising star @ggebraelmd on baseline bone pain as a prognostic marker for survival in mHSPC! @neerajaiims @huntsmancancer @OncLive

0

10

36

1

4

27

Georges Gebrael

@ggebraelmd

1 year

Ab #5049 #ASCO23 @ASCO : In pts receiving 1L Rx for mCRPC #prostatecancer ➡️synchronous (de novo) vs metachronous disease appears to affect OS in pts who received ADT monotherapy but not ADT intensification in the mCSPC setting @neerajaiims @Huntsman_GU @umangtalking @nsayeghmd

0

7

25

Georges Gebrael

@ggebraelmd

7 months

Breaking news @ASCO #GU24 by @DrChoueiri 👉 Ph3 trial of adj pembro vs placebo in pts w/ intermediate-high or high risk RCC #kidneycancer ➡️ OS improved w/ HR 0.62 @urotoday @OncoAlert

0

8

24

Georges Gebrael

@ggebraelmd

2 years

Fruitful discussion with @neerajaiims regarding the TALAPRO-2 trial data #GU23 @ASCO #prostatecancer @urotoday @Uromigos

0

11

24

Georges Gebrael

@ggebraelmd

7 months

Abs #460 @ASCO #GU24 by @EbrahimiHedyeh discussing metabolic pathways in pts with mRCC #kidneycancer treated with cabo + nivo +/- CBM588 @CityofHope_GU

1

8

21

Georges Gebrael

@ggebraelmd

2 years

Checkout Abs #600 by Kosuke Takemura👉Impact of IO-based combination Rx on pts with brain mets ➡️ longer OS vs anti-VEGF monotherapy; Brain-directed local Rx (Surgery or SBRT) ➡️ longer OS @IMDConline @LuisMezaco

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Abs #600 @ASCO #GU23 👉 : In 775 mRCC #kidneycancer pts with brain metastases➡️ OS longer with IO-based Rx vs anti-VEGF monotherapy; and with Brain-directed local Rx @DrDanielHeng @DrChoueiri @KidneyCancer @urotoday @OncoAlert @IMDConline

2

25

43

0

1

19

Georges Gebrael

@ggebraelmd

9 months

Congratulations @neerajaiims et al. for this practice-influencing study published @NatureMedicine on the efficacy of enza + tala vs enza monoRx in pts w/ mCRPC #prostatecancer harboring HRR alterations @lihaoran @vinay_onc @GliceidaGalarza @nsayeghmd @TripNish

Neeraj Agarwal, MD, FASCO

@neerajaiims

9 months

Just in @NatureMedicine 👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer 👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉 @OncoAlert @PCF_Science

17

109

230

0

5

16

Georges Gebrael

@ggebraelmd

1 year

⭐️Just out @TheLancet TALAPRO-2 results➡️one more combination showing improved outcomes for mCRPC patients. Congrats @neerajaiims and team for this milestone @Huntsman_GU @huntsmancancer @umangtalking @maughanonc @vinay_onc @nsayeghmd @TripNish

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science

16

121

310

0

6

14

Georges Gebrael

@ggebraelmd

8 months

Abs21 @ASCO #GU24 👉 Very important data presented by @umangtalking elucidating molecular & immuno differences between primary & metastatic sites & tumor microenv in pts with #prostatecancer @huntsmancancer @Huntsman_GU @carisls

0

4

13

Georges Gebrael

@ggebraelmd

1 year

⭐️Just in @TheLancet #CONTACT03 by @DrChoueiri @montypal : the combo cabo/atezo appears to be similar to cabo monoRx in pts who progressed on prior PD-1/L1 based combo w/⬆️rate of serious adv events➡️PD-L1 rechallenge in mRCC does not seem to be beneficial

Toni Choueiri, MD

@DrChoueiri

1 year

1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type. Kudos to @montypal , SC members, @roche , our patients, = for this phenomenal job.

6

103

255

0

2

14

Georges Gebrael

@ggebraelmd

8 months

Abs539 @ASCO #GU24 by @rohitjainMD 👉 Ph2 PemCab (pembro + cabo) trial in 1L cis-ineligible pts w/ mUC #bladdercancer 👉 ORR 45.7%, PFS 7.6 mo, mOS 17.1 mo @maughanonc @umangtalking @Huntsman_GU @MoffittNews

1

6

13

Georges Gebrael

@ggebraelmd

1 year

Congrats Nishita! Hard work paid off

Nishita Tripathi, MD

@TripNish

1 year

Happy to share that I matched to IM #Match2023 Extremely grateful to my mentors for their unrelenting support & guidance through every step of this journey @neerajaiims @montypal @PGrivasMDPhD @umangtalking @maughanonc & my family at @Huntsman_GU @AbhiTrip87 @AzraBoro88 @TheNRMP

19

9

59

1

0

10

Georges Gebrael

@ggebraelmd

1 year

Congrats @neerajaiims ! Thank you for your dedication in making positive impact in education, advancing the cancer field, and most importantly empowering future leaders to thrive!

Umang Swami

@umangtalking

1 year

Heartiest congratulations to @neerajaiims on being awarded Guy A. Zimmerman, MD Faculty Mentoring Award @huntsmancancer @UUtah @OncoAlert @PCFnews

33

22

141

1

0

10

Georges Gebrael

@ggebraelmd

2 years

Looking forward to the results of the TALAPRO-2 trial tomorrow at #GU23 @ASCO @neerajaiims

Nishita Tripathi, MD

@TripNish

2 years

Exciting discussion on the evolution of emerging therapies for advanced prostate cancer by @neerajaiims @TDorffOnc @DrRanaMcKay #prostatecancer #MedIQGU23

0

11

20

0

1

10

Georges Gebrael

@ggebraelmd

11 months

TTNT & OS w/ 2L cabo were similar after progression on 1L ipi/nivo vs. PD-1/L1i + TKI in pts w/ clear cell mRCC #kidneycancer #ESMO23 Thank you @zklaassen_md for highliting @urotoday @OncoAlert

Zach Klaassen

@zklaassen_md

11 months

Comp Effect of 2L Cabo in mccRCC After 1L Ipi + Nivo vs. PD-1/L1i + TKI #ESMO23 @urotoday @ggebraelmd @neerajaiims @umangtalking 🚩n=237; 145 1L Ipi + Nivo vs 92 1L PD-1/L1i + TKI ➡️ Cabo 🚩TTNT w/ Cabo: 8 mos (95%CI 6.9-11) vs 7.5 mos (95%CI 6.3-16) HR 1.43, 95% CI 0.98–2.11

1

9

12

0

1

9

Georges Gebrael

@ggebraelmd

1 year

@ConquerCancerFd @neerajaiims @ASCO @huntsmancancer @nsayeghmd @eddy_saad @TripNish @vinay_onc @umangtalking @maughanonc @Huntsman_GU @DrDanielHeng @DrChoueiri Shoutout to my brilliant friend and colleague, @eddy_saad , as well as the #IMDC leaders, @DrChoueiri and @DrDanielHeng , for their full support and commitment to advancing the field of kidney cancer

1

0

7

Georges Gebrael

@ggebraelmd

2 years

One of the kindest and most humble too! Congrats Dr @NeliMUlrich @huntsmancancer @Huntsman_GU

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Congrats @NeliMUlrich @huntsmancancer for one of the best scientists award in the USA.👇You are indeed a trail blazer and a role model for all across the globe with your wonderful contributions to science. @BeckerleMary @TomVargheseJr @UUtah @MikeGoodMD

7

11

40

0

5

Georges Gebrael

@ggebraelmd

2 years

Great Job @JamesBrundage8 promising results from this hypothesis generating study 👉low serum iron correlated with worse clinical benefit in patients with clear cell mRCC treated with Ipi/Nivo @KCA_Journal @KidneyCancer @kidneycan @OncoAlert @urotoday @Huntsman_GU

OncLive.com

@OncLive

2 years

Nivolumab/Ipilimumab Generates Worse Responses in Patients With Metastatic Clear Cell RCC With Low Serum Iron @kidneycan #KCRS22 #kcsm #oncology

0

2

6

0

2

5

Georges Gebrael

@ggebraelmd

2 years

Screening saves lives #CancerScreenWeek

Huntsman Cancer Institute

@huntsmancancer

2 years

We are proud to support #CancerScreenWeek . Please join us in helping to raise awareness of the potentially life-saving benefits of early detection.

0

4

6

0

1

5

Georges Gebrael

@ggebraelmd

1 year

@DrChoueiri @neerajaiims @montypal Thank you so much @DrChoueiri for your kind words! Your passion and dedication in the field are truly inspiring

0

4

Georges Gebrael

@ggebraelmd

11 months

@DrChoueiri @neerajaiims @Huntsman_GU @OncoAlert Thank you so much Dr. Choueiri for your incredibly kind words and support!! Means a lot coming from you.

0

1

Georges Gebrael

@ggebraelmd

2 years

@WNMacaron @MDAndersonNews @ECFMG_IMG @StoriesImg @IMG_Advocate @ImgJourney @usa_ilma @Inside_TheMatch @imgsforimgs Best of luck Walid!!

0

4

Georges Gebrael

@ggebraelmd

2 years

@eddy_saad @USJLiban @UWorldMedical @ambossmed @StoriesImg @IMG_Advocate @ImgJourney Congrats legend @eddy_saad ! You will never fail to amaze us!!

0

4

Georges Gebrael

@ggebraelmd

6 months

@shilpaonc @neerajaiims @UofUInternalMed @montypal @DrChoueiri @PGrivasMDPhD @NeliMUlrich @USJLiban Thank you so much @shilpaonc

0

4

Georges Gebrael

@ggebraelmd

1 year

Pilot study to assess #AI as educational resource NOT decision maker, to assist patient NOT physician in #oncology ➡️mostly accurate and not harmful➡️need for developed AI #chatbot based on evidence + intended for medical purposes

Joseph Kassab, MD, MS

@JKassabMD

1 year

🔥Just in🔥 👉🏻 Could #AI -based online chat potentially become a validated tool for assisting in patient #education ? 👉🏻 86% of #ChatGPT answered questions on various #oncology topics were accurate according to #oncologists . @FrontOncology @OncoAlert